SLS 241220 1.50C (SLS241220C1500) Stock Options, News & Quotes

US OptionsDetailed Quotes

SLS241220C1500

Watchlist

0.14
0.000.00%

15min DelayTrading Nov 21 15:59 ET

0.00High0.00Low

Intraday

5D
Daily

No Data

News

We're A Little Worried About SELLAS Life Sciences Group's (NASDAQ:SLS) Cash Burn Rate
Yahoo FinanceNov 16 07:28 ET
Maxim Group Maintains Sellas Life Sciences(SLS.US) With Buy Rating, Maintains Target Price $4
Moomoo NewsNov 15 10:31 ET · Ratings
Promising Clinical Trials and Strong Financial Position Bolster Buy Rating for SELLAS Life Sciences Group
TipRanksNov 15 10:15 ET · Ratings
Sellas Life Sciences Reports Q3 EPS (10c), Consensus (13c)
TipRanksNov 13 16:40 ET
Express News | SELLAS Life Sciences Gr Q3 2024 GAAP EPS $(0.10) Beats $(0.13) Estimate
BenzingaNov 13 16:30 ET
Sellas Life Sciences | 8-K: SELLAS Life Sciences Reports Third Quarter 2024 Financial Results and Provides Corporate Update
SECNov 13 16:23 ET

Comments

steven smith38

Oct 15 07:58

$Sellas Life Sciences (SLS.US)$ try in the houseeeee

Trytosaveabit

Oct 15 07:47

News

$Sellas Life Sciences (SLS.US)$ Reuters· 1 min ago
Sellas Announces U.S. FDA Rare Pediatric Disease Designation (Rpdd) Granted to Galinpepimut-S (Gps) for the Treatment of Pediatric Acute Myeloid Leukemia

Jaguar8

Oct 15 07:45

NEWS

$Sellas Life Sciences (SLS.US)$
SELLAS Announces U.S. FDA Rare Pediatric Disease Designation (RPDD) Granted to Galinpepimut-S (GPS) for the Treatment of Pediatric Acute Myeloid Leukemia
SELLAS Life Sciences Group (NASDAQ: SLS) has received Rare Pediatric Disease Designation (RPDD) from the FDA for Galinpepimut-S (GPS) in treating pediatric acute myeloid leukemia (AML). GPS, an immunotherapeutic targeting Wilms Tumor-1, is currently in a Phase 3 REGAL trial for adult AML patients, with an inte...

Irishman

Oct 14 13:06

Share Your Profit/Loss

Irishman

Sep 20 10:23

Share Your Profit/Loss